Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 12/2018

20.07.2018 | Original Article

A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)

verfasst von: Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou, On behalf of China Gastrointestinal Stromal Tumor Study Group (CN-GIST)

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

To determine the better risk stratification based on surgical pathology and to assess the clinical outcomes after curative resection with a new scoring system in high risk gastrointestinal stromal tumor (GIST) patients.

Methods

We retrospectively evaluated 506 high-risk GIST patients who underwent curative resection as initial treatment at four centers from 2001 to 2015.

Results

Multivariate analysis revealed that only Ki-67 labeling index (LI) and mitotic index were independent prognostic factors of overall survival (OS). For the two tumor-related pathological factors, Ki-67 LI > 7% and mitotic index ≥ 7/50 high power fields were allocated 1 point each. The total score was defined as the Pathological Prognostic Score (PPS). When Ki-67 LI and mitotic index were replaced by PPS, a multivariate analysis still identified PPS as an independent predictor of OS (HR 2.719; 95% CI 1.309–5.650; P = 0.007). Patients with a PPS of 0, 1, or 2 had a 5-year survival of 91.8, 79.8, and 51.0%, respectively (P = 0.001). Furthermore, an elevated PPS (PPS = 2) was associated with larger tumor size, non-stomach tumor, and open resection (all P < 0.05).

Conclusion

The PPS independently predicted postoperative survival in high-risk GIST, and it might facilitate the selection of appropriate treatment strategy for these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCNN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Journal of the National Comprehensive Cancer Network: JNCCN 2010; 8 Suppl 2, S1–41; quiz S42–44.CrossRef Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCNN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Journal of the National Comprehensive Cancer Network: JNCCN 2010; 8 Suppl 2, S1–41; quiz S42–44.CrossRef
2.
Zurück zum Zitat Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (New York, NY) 1998; 279, 577–580.CrossRef Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (New York, NY) 1998; 279, 577–580.CrossRef
3.
Zurück zum Zitat Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53, 245–266.CrossRef Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53, 245–266.CrossRef
4.
Zurück zum Zitat Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369, 1731–1741.CrossRef Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369, 1731–1741.CrossRef
5.
Zurück zum Zitat Kramer K, Knippschild U, Mayer B, Bogelspacher K, Spatz H, Henne-Bruns D, Agaimy A, Schwab M, Schmieder M. Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC cancer 2015; 15, 57.CrossRef Kramer K, Knippschild U, Mayer B, Bogelspacher K, Spatz H, Henne-Bruns D, Agaimy A, Schwab M, Schmieder M. Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC cancer 2015; 15, 57.CrossRef
6.
Zurück zum Zitat Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho MY, Jin SY, Choi JS, Kang DY. Gastrointestinal stromal tumors in Koreans: it’s incidence and the clinical, pathologic and immunohistochemical findings. Journal of Korean Medical Science 2005; 20, 977–984.CrossRef Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho MY, Jin SY, Choi JS, Kang DY. Gastrointestinal stromal tumors in Koreans: it’s incidence and the clinical, pathologic and immunohistochemical findings. Journal of Korean Medical Science 2005; 20, 977–984.CrossRef
7.
Zurück zum Zitat Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Seminars in Diagnostic Pathology 2006; 23, 70–83.CrossRef Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Seminars in Diagnostic Pathology 2006; 23, 70–83.CrossRef
8.
Zurück zum Zitat Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Polish Journal of Pathology : official journal of the Polish Society of Pathologists 2003; 54, 3–24. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Polish Journal of Pathology : official journal of the Polish Society of Pathologists 2003; 54, 3–24.
9.
Zurück zum Zitat Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63, 513–522; discussion 523-514.CrossRef Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63, 513–522; discussion 523-514.CrossRef
10.
Zurück zum Zitat Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, Casali PG, Decatris M, Eriksson M, Gelderblom H, Kosmidis P, Le Cesne A, Pousa AL, Schlemmer M, Verweij J, Joensuu H. Adjuvant therapy in primary GIST: state-of-the-art. Annals of Oncology: official journal of the European Society for Medical Oncology/SMO 2012; 23, 2776–2781.CrossRef Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, Casali PG, Decatris M, Eriksson M, Gelderblom H, Kosmidis P, Le Cesne A, Pousa AL, Schlemmer M, Verweij J, Joensuu H. Adjuvant therapy in primary GIST: state-of-the-art. Annals of Oncology: official journal of the European Society for Medical Oncology/SMO 2012; 23, 2776–2781.CrossRef
11.
Zurück zum Zitat Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, Zheng J, Zhang B, Tzen CY, Yeh CN, Nishida T, Shen L, Chen LT, Kang YK. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer research and treatment : official journal of Korean Cancer Association 2016; 48, 1155–1166.CrossRef Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, Zheng J, Zhang B, Tzen CY, Yeh CN, Nishida T, Shen L, Chen LT, Kang YK. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer research and treatment : official journal of Korean Cancer Association 2016; 48, 1155–1166.CrossRef
12.
Zurück zum Zitat Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schoffski P, Leyvraz S, Italiano A, Grunwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litiere S, Marreaud S, van der Graaf W, Gronchi A, Verweij J. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2017; 35, 1713–1720.CrossRef Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schoffski P, Leyvraz S, Italiano A, Grunwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litiere S, Marreaud S, van der Graaf W, Gronchi A, Verweij J. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2017; 35, 1713–1720.CrossRef
13.
Zurück zum Zitat Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26, 626–632.CrossRef Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26, 626–632.CrossRef
14.
Zurück zum Zitat Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. International Journal of Cancer Journal International du Cancer 2011; 129, 2533–2542.CrossRef Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. International Journal of Cancer Journal International du Cancer 2011; 129, 2533–2542.CrossRef
15.
Zurück zum Zitat Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology 2002; 33, 459–465.CrossRef Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology 2002; 33, 459–465.CrossRef
16.
Zurück zum Zitat Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathology 2008; 39, 1411–1419.CrossRef Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathology 2008; 39, 1411–1419.CrossRef
17.
Zurück zum Zitat Kemmerling R, Weyland D, Kiesslich T, Illig R, Klieser E, Jager T, Dietze O, Neureiter D. Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors. Oncology letters 2014; 7, 745–749.CrossRef Kemmerling R, Weyland D, Kiesslich T, Illig R, Klieser E, Jager T, Dietze O, Neureiter D. Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors. Oncology letters 2014; 7, 745–749.CrossRef
18.
Zurück zum Zitat Klieser E, Pichelstorfer M, Weyland D, Kemmerling R, Swierczynski S, Dinnewitzer A, Jager T, Kiesslich T, Neureiter D, Illig R. Back to the start: evaluation of prognostic markers in gastrointestinal stromal tumors. Molecular and Clinical Oncology 2016; 4, 763–773.CrossRef Klieser E, Pichelstorfer M, Weyland D, Kemmerling R, Swierczynski S, Dinnewitzer A, Jager T, Kiesslich T, Neureiter D, Illig R. Back to the start: evaluation of prognostic markers in gastrointestinal stromal tumors. Molecular and Clinical Oncology 2016; 4, 763–773.CrossRef
19.
Zurück zum Zitat Kang YK, Kang HJ, Kim KM, Sohn T, Choi D, Ryu MH, Kim WH, Yang HK. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer research and treatment: official journal of Korean Cancer Association 2012; 44, 85–96.CrossRef Kang YK, Kang HJ, Kim KM, Sohn T, Choi D, Ryu MH, Kim WH, Yang HK. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer research and treatment: official journal of Korean Cancer Association 2012; 44, 85–96.CrossRef
20.
Zurück zum Zitat Yeh CN, Hwang TL, Huang CS, Lee PH, Wu CW, Chen-Guo K, Jan YY, Chen MF. Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan. World Journal of Surgical Oncology 2012; 10, 246.CrossRef Yeh CN, Hwang TL, Huang CS, Lee PH, Wu CW, Chen-Guo K, Jan YY, Chen MF. Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan. World Journal of Surgical Oncology 2012; 10, 246.CrossRef
21.
Zurück zum Zitat Schmieder M, Henne-Bruns D, Mayer B, Knippschild U, Rolke C, Schwab M, Kramer K. Comparison of different risk classification systems in 558 patients with gastrointestinal stromal tumors after R0-resection. Frontiers in Pharmacology 2016; 7, 504.CrossRef Schmieder M, Henne-Bruns D, Mayer B, Knippschild U, Rolke C, Schwab M, Kramer K. Comparison of different risk classification systems in 558 patients with gastrointestinal stromal tumors after R0-resection. Frontiers in Pharmacology 2016; 7, 504.CrossRef
22.
Zurück zum Zitat Nagasako Y, Misawa K, Kohashi S, Hasegawa K, Okawa Y, Sano H, Takada A, Sato H. Evaluation of malignancy using Ki-67 labeling index for gastric stromal tumor. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2003; 6, 168–172.CrossRef Nagasako Y, Misawa K, Kohashi S, Hasegawa K, Okawa Y, Sano H, Takada A, Sato H. Evaluation of malignancy using Ki-67 labeling index for gastric stromal tumor. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2003; 6, 168–172.CrossRef
23.
Zurück zum Zitat Sakurai S, Fukayama M, Kaizaki Y, Saito K, Kanazawa K, Kitamura M, Iwasaki Y, Hishima T, Hayashi Y, Koike M. Telomerase activity in gastrointestinal stromal tumors. Cancer 1998; 83, 2060–2066.CrossRef Sakurai S, Fukayama M, Kaizaki Y, Saito K, Kanazawa K, Kitamura M, Iwasaki Y, Hishima T, Hayashi Y, Koike M. Telomerase activity in gastrointestinal stromal tumors. Cancer 1998; 83, 2060–2066.CrossRef
24.
Zurück zum Zitat Wen S, Zhou W, Li CM, Hu J, Hu XM, Chen P, Shao GL, Guo WH. Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies. BMC Cancer 2015; 15, 520.CrossRef Wen S, Zhou W, Li CM, Hu J, Hu XM, Chen P, Shao GL, Guo WH. Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies. BMC Cancer 2015; 15, 520.CrossRef
25.
Zurück zum Zitat Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, Lotan Y, Margulis V. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU international 2014; 113, 668–673.CrossRef Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, Lotan Y, Margulis V. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU international 2014; 113, 668–673.CrossRef
26.
Zurück zum Zitat Lumachi F, Orlando R, Marino F, Chiara GB, Basso SM. Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer. Anticancer Research 2012; 32, 3965–3967.PubMed Lumachi F, Orlando R, Marino F, Chiara GB, Basso SM. Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer. Anticancer Research 2012; 32, 3965–3967.PubMed
27.
Zurück zum Zitat Belev B, Brcic I, Prejac J, Golubic ZA, Vrbanec D, Bozikov J, Aleric I, Boban M, Razumovic JJ. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors. World Journal of Gastroenterology: WJG 2013; 19, 523–527.CrossRef Belev B, Brcic I, Prejac J, Golubic ZA, Vrbanec D, Bozikov J, Aleric I, Boban M, Razumovic JJ. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors. World Journal of Gastroenterology: WJG 2013; 19, 523–527.CrossRef
28.
Zurück zum Zitat Pyo JS, Kang G, Sohn JH. Ki-67 labeling index can be used as a prognostic marker in gastrointestinal stromal tumor: a systematic review and meta-analysis. The International Journal of Biological Markers 2016; 31, e204–210.CrossRef Pyo JS, Kang G, Sohn JH. Ki-67 labeling index can be used as a prognostic marker in gastrointestinal stromal tumor: a systematic review and meta-analysis. The International Journal of Biological Markers 2016; 31, e204–210.CrossRef
29.
Zurück zum Zitat Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Lin TL, Shen YY, Liu Q, Cao H. Prognostic value of Ki67 index in gastrointestinal stromal tumors. International Journal of Clinical and Experimental Pathology 2014; 7, 2298–2304.PubMedPubMedCentral Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Lin TL, Shen YY, Liu Q, Cao H. Prognostic value of Ki67 index in gastrointestinal stromal tumors. International Journal of Clinical and Experimental Pathology 2014; 7, 2298–2304.PubMedPubMedCentral
30.
Zurück zum Zitat D’Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. European Journal of Cancer (Oxford, England: 1990) 2017; 78, 122–132.CrossRef D’Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. European Journal of Cancer (Oxford, England: 1990) 2017; 78, 122–132.CrossRef
31.
Zurück zum Zitat Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373, 1097–1104.CrossRef Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373, 1097–1104.CrossRef
32.
Zurück zum Zitat Joensuu H. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management. Drugs 2012; 72, 1953–1963.CrossRef Joensuu H. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management. Drugs 2012; 72, 1953–1963.CrossRef
33.
Zurück zum Zitat Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegard T, Reichardt P. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307, 1265–1272.CrossRef Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegard T, Reichardt P. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307, 1265–1272.CrossRef
34.
Zurück zum Zitat Lin JX, Chen QF, Zheng CH, Li P, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang CM. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. Journal of Cancer Research and Clinical Oncology 2017; 143, 727–734.CrossRef Lin JX, Chen QF, Zheng CH, Li P, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang CM. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. Journal of Cancer Research and Clinical Oncology 2017; 143, 727–734.CrossRef
Metadaten
Titel
A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
verfasst von
Xuechao Liu
Haibo Qiu
Zhiming Wu
Peng Zhang
Xingyu Feng
Tao Chen
Yong Li
Kaixiong Tao
Guoxin Li
Xiaowei Sun
Zhiwei Zhou
On behalf of China Gastrointestinal Stromal Tumor Study Group (CN-GIST)
Publikationsdatum
20.07.2018
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 12/2018
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-018-3799-5

Weitere Artikel der Ausgabe 12/2018

Journal of Gastrointestinal Surgery 12/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.